Vanguard Group Inc Y M Abs Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.57 Trillion
- Q4 2024
A detailed history of Vanguard Group Inc transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,000,022 shares of YMAB stock, worth $11.4 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,000,022
Previous 2,035,363
1.74%
Holding current value
$11.4 Million
Previous $26.7 Million
41.4%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding YMAB
# of Institutions
113Shares Held
26.9MCall Options Held
5.6KPut Options Held
900-
Paradigm Biocapital Advisors LP New York, NY4.24MShares$24.2 Million1.27% of portfolio
-
Black Rock Inc. New York, NY2.94MShares$16.8 Million0.0% of portfolio
-
Acorn Capital Advisors, LLC New York, NY2.86MShares$16.4 Million12.11% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.19MShares$12.6 Million1.4% of portfolio
-
Polar Capital Holdings PLC London, X01.83MShares$10.5 Million0.09% of portfolio
About Y-mAbs Therapeutics, Inc.
- Ticker YMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,719,500
- Market Cap $250M
- Description
- Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...